Remimazolam: The future of its sedative potential
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Remimazolam (CNS 7056) is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia – Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil. It is likely to be the sedative of the future, as preliminary phase II trials have shown minimal residual effects on prolonged infusions. It has potential to be used as a sedative in ICU and as a novel agent for procedural sedation. Unlike most rapidly acting intravenous sedatives available presently, the propensity to cause apnea is very low. Availability of a specific antagonist (flumazenil) adds to its safety even in cases of overdose. The present review discusses remimazolam's potential as a new drug in anesthesia along with the presently available literary evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kilpatrick (2007) · doi:10.1097/01.anes.0000267503.85085.c0 · Cited by 381
Wiltshire, H. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318241f68a · Cited by 215 · cited 1×
“In the clinical doses, the enzymes are unlikely to be saturated and as a result, there is no accumulation reported.[6,7] In other words, the rate of reaction continues to follow fi rst order kinetics and is unlikely to change to zero order in the recommended doses.”
Background
Cited by
Remimazolam: pharmacological characteristics and clinical applications in anesthesiology
Kim, K. M. (2022) · Anesthesia and Pain Medicine · doi:10.17085/apm.21115 · Cited by 257
Efficacy and safety of remimazolam in endoscopic sedation-A systematic review and meta-analysis
Zhu, X., Wang, H., Yuan, S., Li, Y., Jia, Y., Zhang, Z., Yan, F., & Wang, Z. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655042 · Cited by 75
Induction and maintenance of procedural sedation in adults: focus on remimazolam injection
Chen, W., Chen, S., & Huang, Y. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1901575 · Cited by 25
“safely administered in patients with impaired liver or renal function as its elimination is expected to be organ independent [19].”
BackgroundInfluentialHu, K., Xiang, Q., Wang, Z., Sheng, X., Li, L., Liang, Y., Zhao, X., Ye, X., & Cui, Y. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.797 · Cited by 17
WEGNER, B. M., WEGNER, G. M., SPAGNOL, L. W., COSTA, L. A., SPAGNOL, V. W., & PAIVA, D. F. (2024) · Minerva Anestesiologica · doi:10.23736/s0375-9393.24.18041-8 · Cited by 19
Metadata
- Authors
- Goudra, B. G., & Singh, P. M.
- Venue
- Saudi Journal of Anaesthesia
- Published
- 2014-07
- Volume
- 8
- Issue
- 3
- Pages
- 388-391
- ISSN
- 0975-3125 (ISSN-L)
- 1658-354X
- OpenAlex
- W2059865921
- Cited by
- 97
- References
- 2
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remimazolam: The future of its sedative potential. https://app.cochat.ai/papers/10.4103/1658-354x.136627
- The paper
- Goudra, B. G., & Singh, P. M. (2014). Remimazolam: The future of its sedative potential. Saudi Journal of Anaesthesia. https://doi.org/10.4103/1658-354x.136627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.